
Feb 19 (Reuters) - Recce Pharmaceuticals Ltd RCE.AX:
RECCE PHARMACEUTICALS REPORTS POSITIVE DATA FROM PHASE II TRIAL OF RECCE® 327 GEL IN ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS, SUPPORTING ACCELERATED COMMERCIALIZATION PATHWAY
RECCE PHARMACEUTICALS LTD - R327G ACHIEVES 93% PRIMARY EFFICACY ENDPOINT IN 14 DAYS
RECCE PHARMACEUTICALS LTD - R327G SAFE AND WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS
Source text: ID:nGNX6kyg2r
Further company coverage: RCE.AX